Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2015 Jan 15;25(2):229-35. doi: 10.1016/j.bmcl.2014.11.063. Epub 2014 Nov 27.

Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model.

Author information

1
Lead Identification and Optimization Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach a.d. Riss, Germany. Electronic address: jan.kriegl@boehringer-ingelheim.com.
2
Medicinal Chemistry, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach a.d. Riss, Germany.
3
Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach a.d. Riss, Germany.
4
Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach a.d. Riss, Germany.
5
Lead Identification and Optimization Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, D-88397 Biberach a.d. Riss, Germany.

Abstract

Rodent selectivity data of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists, are presented and discussed as part of an overall optimization effort within this lead compound class. Although attachment of an acidic moiety to the 1-position of the indole led to an overall balanced in vitro profile, in particular reducing inhibition of the hERG channel, potency on the rat and mouse receptor worsened. These findings could be rationalized in the context of a CCR3 homology model.

KEYWORDS:

CCR3; Chemokine; Piperidine-4-yl-1H-indoles; Receptor model; Rodent selectivity; hERG

PMID:
25497216
DOI:
10.1016/j.bmcl.2014.11.063
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center